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doi:10.1016/j.jtcvs.2004.03.041442 The Journal of Thoracic and CardioObjective: Despite proven blood transfusion benefits, aprotinin may be underused in
coronary artery bypass grafting. Reluctance to use aprotinin may stem from safety
concerns. The current objective was to evaluate clinical outcomes (mortality,
myocardial infarction, renal failure, stroke, atrial fibrillation) in patients undergoing
coronary artery bypass grafting who receive aprotinin by performing a quantitative
overview of published, randomized, controlled trials.
Methods: MEDLINE, EMBASE, and PHARMLINE (1988-2001) and reference
lists of relevant articles were searched for coronary artery bypass grafting studies.
Criteria for data inclusion were as follows: (1) random allocation of study treat-
ments, (2) placebo control, (3) enrollment only of patients undergoing coronary
artery bypass grafting, (4) no combination with another experimental medication or
device, and (5) prophylactic and continuous intraoperative use.
Results: Data from 35 coronary artery bypass grafting trials (n 3879) confirm that
aprotinin reduces transfusion requirements (relative risk 0.61, 95% confidence
interval 0.58-0.66) relative to placebo, with a 39% risk reduction. Aprotinin therapy
was not associated with increased or decreased mortality (relative risk 0.96, 95%
confidence interval 0.65-1.40), myocardial infarction (relative risk 0.85, 95% con-
fidence interval 0.63-1.14), or renal failure (relative risk 1.01, 95% confidence
interval 0.55-1.83) risk, but it was associated with a reduced risk of stroke (relative
risk 0.53, 95% confidence interval 0.31-0.90) and a trend toward reduced atrial
fibrillation (relative risk 0.90, 95% confidence interval 0.78-1.03).
Conclusions: Aprotinin reduces transfusion requirements. Concerns that aprotinin
therapy is associated with increased mortality, myocardial infarction, or renal failure
risk is not supported by data from published, randomized, placebo-controlled
clinical trials. Evidence for a reduced risk of stroke and a tendency toward reduction
of atrial fibrillation occurrence was observed in patients who received aprotinin.
Aprotinin (Trasylol) is the only pharmacologic treatment approvedby the US Food and Drug Administration to reduce blood trans-fusion in coronary artery bypass grafting (CABG). The use ofaprotinin in CABG has been associated with more than 45%reduction in blood transfusion relative to placebo in many largemulticenter trials.1-3 Growing literature relating blood transfusion
to adverse outcomes and associated costs heightens the need to use strategies to
reduce transfusion.
A reluctance by surgeons to use aprotinin routinely may result from concerns
about the risk of a possible procoagulable state, including such adverse outcomes as
myocardial infarction (MI), stroke, and atrial fibrillation, induced by an agent that
reduces blood loss. Although some side effects (MI and renal failure) have been
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ciations is limited and primarily based on case series.5 A
recent prospective, uncontrolled, observational study re-
ported that therapy with antifibrinolytic agents including
aprotinin was associated with increased mortality,6 whereas
a previous literature review analysis7 showed aprotinin use
to be associated with decreased mortality. The latter study
addressed safety and efficacy of aprotinin use in cardiac
surgery by analyzing a mixture of cardiac surgical proce-
dures; the study,7 however, did not address important clin-
ical end points reported in more recent studies, such as
stroke8 and atrial fibrillation.9 In addition, numeric discrep-
ancies in the evaluation7 led to the criticism that a more
rigorous analysis was required.10
This investigation analyzed the association of aprotinin
with mortality, myocardial infarction, renal failure, stroke,
and atrial fibrillation by performing a rigorous quantitative
overview of all randomized, controlled trials of aprotinin in
CABG. As a secondary end point, the relationship of apro-
tinin administration to the reduced risk of blood transfusion
was calculated. The impact of preoperative aspirin use on
these clinical outcomes was also evaluated.
Methods
Selection of Trials
Only trials enrolling patients undergoing CABG were included,
because that is the only indication approved by the US Food and
Drug Administration for aprotinin use in cardiac surgery. Random-
ized clinical trials of aprotinin use in CABG were identified by
searching the MEDLINE, EMBASE, and PHARMLINE databases
(1988-2001 through MEDLINE) with the key words aprotinin or
trasylol in combination with coronary-artery-bypass*:Me, coro-
nary and bypass, myocardial revascularization, aortocoronary
and bypass, aortocoronary and shunt, aortocoronary and anasto-
mosis, coronary and graft, and coronary and surgery. A standard
filter designed by the Cochrane Collaboration for identifying ran-
domized clinical trials was used for MEDLINE and EMBASE
(adopted from Scottish Intercollegiate Guideline Network [http://
www.sign.ac.uk/methodology/filters.html]). In addition, reference
lists of published trials of aprotinin were searched for additional
studies. The initial widest search produced 112 English-language
and 3 non–English language articles. Then criteria for study in-
clusion in the overview were applied, which were as follows: (1)
random allocation of study treatments, (2) placebo control, (3)
enrollment of only patients undergoing CABG, (4) no combination
with another experimental medication or device, and (5) preoper-
ative and continuous intraoperative use (studies with only pump
prime use or only postoperative use of aprotinin were excluded).
After initial screening of abstracts, 72 studies appeared to conform
to the inclusion criteria. After evaluating full reports of all 72
studies, 9 studies were excluded because of only pump prime use
of aprotinin (aprotinin used as a single bolus in the cardiopulmo-
nary pump with no continuous infusion; see Appendix Figure 1,
1-9, available online). Another 8 studies were excluded because of
enrollment of both patients undergoing CABG and those under-
going valve operation (see Appendix Figure 1, 10-17, available
The Journal of Thoracionline). Thorough analysis of the remaining reports found 2 stud-
ies in which patients were not randomly assigned to placebo and
active treatment groups (see Appendix Figure 1, 18,19, available
online), another study that was a subgroup analysis (see Appendix
Figure 1, 20, available online), and another study in which recom-
binant aprotinin was used (see Appendix Figure 1, 21, available
online). Fifty-one studies remained. Contact with all 51 corre-
sponding authors was attempted by e-mail or facsimile transmis-
sion to clarify and gain additional data not published in the report.
Current contact information of corresponding authors was gleaned
from recent publications cited in MEDLINE and the World Wide
Web. Data were used only from articles that reported adverse event
information of interest, and those adequately supplemented by
personal communication with the primary investigator; therefore a
final 16 studies were not included (see Appendix Figure 1, 22-37,
available online). The remaining 35 trials (45 published articles)
reported information on any outcomes of interest (mortality, MI,
renal failure, stroke, and atrial fibrillation) and met predefined
criteria to be selected for the overview (see Appendix Figure 1,
38-82, available online).
Data Collection
For each trial, abstracted data included the frequencies of the
events in the aprotinin (full-dose, low-dose, or other) and placebo
groups, as well as the numbers of patients randomly allocated to
the treatment groups. Information on methodologic quality of the
included studies, such as method of randomization, blinding and
its methodology, group comparability, and information on similar
treatment and follow-up after randomization was also collected.
Additional abstracted data included surgical history of the patients
(primary CABG trials versus mixed [including both primary and
reoperative CABG] trials or only reoperative CABG trials), pre-
operative (within 7 days) aspirin use, mean age, gender, race, left
ventricular ejection fraction, and the publication date. One of the
authors (A.S.) abstracted the data, and another author (J.A.E.)
participated in adjudication of any discrepancies.
Mortality reported in all trials included only in-hospital deaths.
The criterion for defining MI was “definite MI” report according to
Minnesota coding classification,11 or in the absence of such coding
information, the reports of “new Q-wave MI.” The criterion for
defining renal failure was the report of this event as clinical
diagnosis. Most of the trials that reported renal failure did not
report assessment method. However, trials funded by a pharma-
ceutical company reported a definition of renal failure as any of the
following diagnoses: “anuria,” “kidney failure,” “acute kidney
failure,” “kidney tubular necrosis,” and “uremia.” The criteria for
the evaluation of stroke frequency were clinical diagnosis of
“stroke” and “severe neurologic deficit.” In addition, such diag-
noses as “cerebrovascular accident,” “cerebral embolism,” “cere-
bral hemorrhage,” “cerebral infarct,” and “cerebral ischemia” were
considered. The definition of atrial fibrillation was based on clin-
ical diagnosis of that event.
Although the methods of ascertainment of the events were not
standardized among the trials, within each trial they were applied
equally to the treatment groups. Reports and descriptions such as
“no major complications were observed in the study” were not
considered to represent 0 events. Only explicit description of the
absence of any outcome event was considered as 0 events.
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Methodologic quality of included studies was evaluated according
to Jadad and coworkers’ criteria,12 which are based on following:
1. “Randomized” study description
2. Description of correct randomization procedure
3. “Double-blinding” study description
4. Description of correct double-blinding
5. Dropouts and adequate description of the end points of
interest
Statistical Analysis
The risk estimates for mortality, MI, renal failure, stroke, and atrial
fibrillation in the aprotinin and placebo groups were assessed
separately. Information from the trials was combined with the
general inverse variance-based method,13 which incorporates a
fixed-effect model and assumes that studies under examination
share a common true effect size, that the sampling distribution of
these effects is normal, and that all the variability is due to
sampling error (homogeneity assumption). In this model, the
weights of individual studies correspond to the inverse of the total
variance for each study. Numbers-needed-to-treat and their confi-
dence intervals (CIs) were also calculated using risk difference
(RD) analysis. RD statistics were particularly important in the
trials with 0 events, in which relative risk (RR) was not estimable.
In these instances RD statistics still provided an estimate of un-
certainty around 0. On the basis of number-needed-to-treat statis-
tics, number of events averted or induced were calculated per 1000
patients undergoing CABG.
The assumption of homogeneity was tested with the 2 statistic,
formed by summing the weighted difference between each indi-
vidual estimate and the pooled estimate. This assumption was
rejected in only instance of blood transfusion analysis. To account
for this, a random effect model was applied to estimate the vari-
ance component associated with between-study variation.14 Ac-
cording to this method, the variance for each individual study in
the overview is the sum of within- and between-study components
of the variance. However, the estimate from this model was not
Figure 1. Reported outcomes and blood transfusion
detailing numbers of events and patients randomized a
to methods described in Statistical Analysis section.different from a fixed-effect model; thus rejection of homogeneity
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fixed-effect model results are reported in this article.
Sensitivity analyses were performed to evaluate the importance
of methodologic quality. This factor was not found to have sub-
stantial influence on the results. RevMan 4.1 (Cochrane Collabo-
ration, http://www.cc-ims.net/RevMan) was used for all statistical
analyses.
Results
A total of 35 trials were included in the overview, involving
more than 3887 patients (see Appendix Table 1, available
online). Most of the studies were double-blind. Age (mean
60.9 years) was reported in 32 randomized trials. Gender
was reported in 28 trials, and on average only 16% of study
participants were female. Patient race was reported in only
3 randomized trials. In 3 other trials, patient race was
determinable from the study country of origin.15-17 Reop-
erative CABG was performed in 13.7% of participants as
reported in 29 trials.
Full-dose aprotinin was used in 29 trials, whereas low-
dose or some other dose was used in 12 trials. Both full-dose
and low-dose or other dose aprotinin were used in 6 trials.
Aspirin use within a 7-day preoperative period was reported
in 27 trials. In 14 of these trials, patients receiving aspirin
within the 7-day preoperative period were excluded by the
investigators, whereas in the other 13 trials, patients were
not excluded on the basis of this criterion.
Mortality
Mortality was assessed in 32 randomized trials including
3779 patients (Figure 1; Appendix Table 2, available on-
line). The overall occurrences of death were similar in
combined (full-dose, low-dose) aprotinin (2.47%) and pla-
cebo (2.40%) groups, and no significant increased risk of
irements in the aprotinin and placebo groups. Data
mulative for all trials; RRs were calculated accordingrequ
re cumortality was associated with use of aprotinin (RR 0.96,
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difference between the groups per 1000 patients undergoing
CABG (95% CI 10 to 10).
MI
MI was assessed in 28 trials including 3555 patients (Figure
1; Appendix Table 2, available online). The occurrence of
MI was moderately high in both aprotinin (4.74%) and
placebo (5.03%) groups. A tendency toward reduction of
the risk of MI in the aprotinin group was relative to placebo
(RR 0.85, 95% CI 0.63-1.14); however, it did not reach
statistical significance at the 5% level. RD statistics calcu-
lated for 1000 patients determined a similar tendency (RD
10, 95% CI 20 to 10). Sensitivity analyses with exclu-
sion of an early study of aprotinin4 (in which increased risk
of MI was reported and monitoring of anticoagulation not
fully appropriate) or the largest study1 (favoring aprotinin
despite concerns related to graft closure) showed no sub-
stantial influence on the estimate of RR (range 0.79-0.87).
Renal Failure
Renal failure data were available in 17 trials including 3003
patients (Figure 1; Appendix Table 2, available online).
Renal failure incidence also did not vary by study group
(aprotinin 1.48%, placebo 1.28%). Meta-analytic estimate
for renal failure also did not show increased risk associated
with aprotinin therapy (RR 1.01, 95% CI 0.55-1.83). Sim-
ilarly, RD statistics showed 0 events averted or induced per
1000 patients undergoing CABG when aprotinin was com-
pared with placebo (95% CI 10 to 10).
Stroke
Stroke was reported in 18 trials and evaluated in 2976
patients (Figure 1; Appendix Table 2, available online).
Aprotinin use was associated with consistently fewer
strokes in most of the individual trials. Stroke occurred in
1.10% of aprotinin and 2.22% of placebo groups. Aprotinin
use was associated with a 47% RR reduction (RR 0.53, 95%
CI 0.31-0.90) relative to placebo. The exclusion of a trial in
which the quality of diagnosis of cerebrovascular accident
was questionable and not confirmed in personal communi-
cation17 had little influence on the magnitude of the asso-
ciation (RR 0.49). RD statistics showed a 10-event reduc-
tion per 1000 patients undergoing CABG treated with
aprotinin (95% CI 20, 0) relative to placebo.
Atrial Fibrillation
Only 11 studies (Figure 1; Appendix Table 2, available
online) involving 2460 patients reported information on
atrial fibrillation. The occurrences of atrial fibrillation re-
ported in individual trials were substantial in both aprotinin
(22.72%) and placebo (25.00%) groups. A tendency toward
risk reduction associated with aprotinin use was observed
(RR 0.90, 95% CI 0.78-1.04). RD statistics also showed a
The Journal of Thoracitendency toward a more than 30 event reduction (per 1000
CABGs) associated with the use of aprotinin (95% CI 60
to 10).
Blood Transfusion
The number of patients who required any blood transfusion
was evaluated in 25 trials involving 3430 patients (Figure 1;
Appendix Table 2, available online). The use of aprotinin
was consistently associated with fewer patients requiring
any blood transfusion. Total numbers of patients requiring
any blood transfusion were 40.33% in aprotinin and 63.34%
in placebo groups. Accordingly, a 39% risk reduction of
blood transfusion was associated with use of aprotinin (RR
0.61, 95% CI 0.58-0.66). RD statistics determined that RR
of this magnitude corresponded to more than 250 patients
prevented from receiving any blood transfusion per 1000
CABG procedures (95% CI 280 to 220).
Events by Subgroups of Preoperative Aspirin Use
Subgroup analyses stratified by aspirin use were evaluated
in fewer trials (Figure 2). In addition, sufficient numbers of
events were available regarding only three outcomes (mor-
tality, MI, and blood transfusion). Presence or absence of
aspirin use had no impact on mortality as related to aproti-
nin therapy. The stratified analysis shows that in trials where
aspirin users within 5 to 7 days before surgery were ex-
cluded, aprotinin use was associated with statistically sig-
nificant risk reduction in the occurrence of MI (RR 0.40,
95% CI 0.17-0.92). In trials where aspirin users were not
excluded, no difference between aprotinin and placebo
groups was observed regarding the occurrence of MI (RR
1.00, 95% CI 0.71-1.40). In addition, fewer patients re-
quired blood transfusion in trials where aspirin users were
excluded (RR 0.53, 95% CI 0.47-0.60) than in trials where
aspirin users were not excluded (RR 0.67, 95% CI 0.61-
0.72).
Discussion
Our quantitative systematic overview of clinical endpoints
indicates that aprotinin therapy is not associated with in-
creased risks of mortality, MI, or renal failure. In contrast,
a tendency toward a reduction of MI was observed among
patients treated with aprotinin relative to placebo. More-
over, use of aprotinin was associated with a 47% reduction
in stroke and tended to be associated with a reduced risk of
atrial fibrillation. Aprotinin therapy was also associated
with a 39% reduction in the number of patients requiring
blood transfusion.
Concerns about MI (graft closure) and renal failure may
contribute to relative underuse of this medication in CABG.
The contention that aprotinin might be associated with MI
and renal failure originated when Cosgrove and colleagues4
reported overall 14 MI events among 113 patients treated
c and Cardiovascular Surgery ● Volume 128, Number 3 445
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Although substantial increase in creatinine was also re-
ported in aprotinin-treated patients, occurrence of renal fail-
ure itself was not different between the groups (8 of 133 vs
4 of 56 in the clinical study report). Although a similar trend
was reported in another well-known clinical trial,18 evi-
dence linking aprotinin to these side events was limited.
Further studies on coagulation monitoring have shown that
aprotinin increases the activated clotting time in the Celite-
based measurement,19 which could potentially lead to un-
derheparinization and contribute to the observed findings in
studies conducted earlier. Although increased or decreased
risks of MI and renal failure cannot be definitely excluded
(because of wide confidence intervals), our findings should
alleviate concerns that aprotinin causes increases in the
occurrence of these adverse events.
One previous study attempting to address systematically
the issue of mortality and MI found aprotinin to be associ-
ated with reduced mortality and slightly higher risk of MI.7
However, the analysis included a mixture of cardiac surgical
procedures (mitral valve, aortic valve, coronary bypass,
etc). In addition, others have indicated concerns about in-
accuracies in patient numbers, discrepancies in odds ratios
Figure 2. Reported outcomes and blood transfusion req
aspirin users (upper panel) and nonusers (lower panel
users if investigators did not exclude patients taking
events and patients randomized are cumulative for all t
in Statistical Analysis section.extracted from individual studies, and inappropriate appli-
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draw from this previous systematic analysis.10 A recent
report suggested that antifibrinolytic therapy, including
aprotinin, increased mortality among patients undergoing
CABG.6 The study used data from studies in which treat-
ment group assignment was not described as randomized or
controlled; thus treatment bias or use of antifibrinolytics as
rescue therapy, instead of as prophylaxis for bleeding, could
well explain the data in this observational study. In our
analysis of aprotinin therapy, no decrease or increase in
mortality was confirmed; the data showed aprotinin therapy
to be associated with a mortality risk ratio of 0.96 (95% CI
0.65, 1.40). In addition, no tendency toward an increased
occurrence of MI in aprotinin treated patients was shown,
and in fact the opposite tendency was observed.
To our knowledge, this is the first systematic analysis
study to report that substantial stroke reduction benefits
could theoretically be associated with aprotinin use, sup-
porting an observation originally published by Levy et al.2
The current analysis indicates that approximately 10 cere-
brovascular accidents can be averted per 1000 patients
undergoing CABG when aprotinin is used. A number of
theories describing the effect of aprotinin on risk of stroke
ents in the aprotinin and placebo groups stratified by
dy participants were considered preoperative aspirin
rin 7 days before surgery. Data detailing numbers of
RRs were calculated according to methods describeduirem
). Stu
aspi
rials;have been discussed. As early as 1994, Murkin and associ-
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tinin may have cerebroprotective effects and proposed that
aprotinin could prevent or ameliorate the initial endothelial
response in the presence of ischemic cerebral injury and
could improve the outcome after cerebral ischemia. Later,
Smith and Muhlbaier5 also reported a tendency toward
stroke reduction in a combined analysis of US aprotinin
trials. In a review study, Royston21 also reported that anti-
inflammatory actions and modifications in vascular tone
associated with aprotinin therapy may be related to im-
proved outcome by reducing the occurrence of permanent
neurologic deficit or stroke after heart operations. A recent
retrospective analysis of a cardiac surgery population at
high risk for stroke8 observed a significant decrease in the
occurrence of stroke among patients administered full-dose
aprotinin relative to the placebo group. Our investigation
provides additional data describing the cerebrovascular ef-
fect of aprotinin. The tendency toward a reduction in atrial
fibrillation associated with aprotinin, supporting clinical
data published previously,9,22 provides another possible
mechanism. Atrial fibrillation is associated with a higher
risk of cerebrovascular accidents, particularly in the early
postoperative period, so the tendency toward prevention of
approximately 30 atrial fibrillations per 1000 patients un-
dergoing CABG could potentially contribute to the obser-
vation of fewer strokes associated with aprotinin.
In our study, the number of patients averted from receiv-
ing any blood transfusion when treated with aprotinin was
accurately quantified. Although blood transfusion benefits
associated with aprotinin have been reported at length,1-4 a
summary estimate with the large population (n  3430)
generated in this study has not been reported previously in
the literature. These data demonstrate that relative to pla-
cebo approximately 250 of 1000 patients undergoing CABG
could theoretically be prevented from any blood transfusion
if treated with aprotinin.
Subgroup analysis of patients enrolled in the trials in
which aspirin users were excluded showed aprotinin therapy
to have no influence on mortality; however, a reduction in
the occurrence of MI was observed. The reduction in MI is
likely to result from some aspect of aprotinin action other
than its ability to reduce blood transfusion requirements.
However, these findings should be interpreted with caution,
because fewer patients were enrolled in these trials. Simi-
larly, we found that neither full-dose regimen nor low-dose
regimen was associated with more frequent adverse events
relative to placebo (data not included). Although full-dose
aprotinin seemed to be associated with a higher reduction in
the transfusion requirements (RR 0.59, 95% CI 0.55-0.64)
than low-dose aprotinin (RR 0.65, 95% CI 0.59-0.72), com-
parison of these two regimens is a question of its own, and
these results need to be confirmed in a more specific meta-
The Journal of Thoracianalyses that also include trials without a placebo arm that
directly compare these regimens.
Conclusions
Aprotinin substantially decreases transfusion requirements
in patients undergoing CABG. The concern that aprotinin
therapy is associated with increased risk of mortality, MI, or
renal failure is not supported by data from published, ran-
domized, placebo-controlled clinical trials. For stroke, evi-
dence of a reduced risk associated with aprotinin therapy
was shown. A tendency toward reduction in atrial fibrilla-
tion occurrence associated with aprotinin use was observed.
The balance of effects is positive with aprotinin use.
We thank all the authors of articles detailing prospective,
randomized, clinical evaluations of aprotinin use in coronary artery
bypass grafting. We acknowledge Jennifer Maurer, PhD, for her
excellent editorial work.
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